
    
      The SPIRIT FIRST clinical trial will enroll approximately 60 patients and will assess the
      feasibility and performance of the XIENCE V® Everolimus Eluting Coronary Stent System in the
      treatment of patients with de novo native coronary artery lesions. In this trial, the XIENCE
      V® Everolimus Eluting Coronary Stent System will be compared to the MULTI-LINK VISION®
      metallic stent which is CE marked and FDA approved and is available for commercial use in
      Europe and in the United States. The SPIRIT FIRST Clinical trial will enroll approximately 60
      patients (30 patients in the test arm and 30 patients in the control arm) with de novo native
      coronary artery lesions in 4 clinical sites in The Netherlands and Germany
    
  